Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...

Acumen Pharmaceuticals, Inc. ( (ABOS) ) has released its Q3 earnings. Here is a breakdown of the information Acumen Pharmaceuticals, Inc.

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

East Windsor is excited to welcome another pharmaceutical company Rising Pharmaceuticals to join the many other high-tech ...

Tharimmune (THAR) announced that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric ...

Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

Since 1885, the UI’s College of Pharmacy has maintained several well-known programs while educating and training pharmacists ...

For more established or competitive markets, having launch experience in the therapeutic areas and/or an existing ... We ...

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

Acadia Pharmaceuticals sold its priority review voucher for $150 million. Haleon named Vistar Media, a location-based ad ...

GlobalData analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's ...

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic ...